Aug. 6 (Bloomberg) -- Amgen, the drugmaker in pursuit of Onyx Pharmaceuticals, boosted its offer for the company to $130 a share, according to a person familiar with the matter. Olivia Sterns reports on Bloomberg Television's "Street Smart." (Source: Bloomberg)
28:23 - Manish Singh, strategist and investment head at Crossbridge Capital, discusses his investment strategy with the prospect of a rate hike by the Federal Reserve. He speaks on "The Pulse." (Source: Bloomberg)
Are Write-Offs Inevitable in Greek Debt Crisis?
Are Japan's Inflation Woes Ignored in Military Debate?
BG Group Second-Quarter Profit Declines 65%
Please upgrade your Browser
Your browser is out-of-date. Please download one of these excellent browsers: